Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900664 · ClinicalTrials.gov registry record · Phase 1
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 283
- Enrollment target
NCT02900664: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT02900664 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 283 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (372% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02900664, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 283 participants
- Enrollment target
Study Summary
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Interventions
- BIOLOGICAL PDR001
- BIOLOGICAL CJM112
- BIOLOGICAL ACZ885
- DRUG TMT212
- DRUG EGF816
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2016-08-23 |
| Est. Completion | 2021-03-17 |
| Phase | Phase 1 |
What the finished NCT02900664 record still lists
NCT02900664 is an interventional study that assigns participants to a tested intervention. The registered 283 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (372% higher).
The record links to 0 conditions, and to 5 interventions - of which PDR001 is the first listed.
NCT02900664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02900664 about?
NCT02900664 is a clinical study titled "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)". The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combination...
What is the current status of trial NCT02900664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 283 participants. The study started on 2016-08-23. Estimated completion is 2021-03-17.
What interventions are being tested in trial NCT02900664?
The interventions under investigation include: PDR001 (BIOLOGICAL), CJM112 (BIOLOGICAL), ACZ885 (BIOLOGICAL), TMT212 (DRUG), EGF816 (DRUG).
Who is sponsoring clinical trial NCT02900664?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02900664's enrollment target sits among peer trials
283 139th of 2000 higher than 1,862 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06856694 · 283 participants · NA
RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI